Synopsis
Synopsis
0
VMF
0
Canada
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Alcon, Betaxolol
2. Alo 1401 02
3. Alo-1401-02
4. Alo140102
5. Betaxolol
6. Betaxolol Alcon
7. Betoptic
8. Betoptima
9. Hydrochloride, Betaxolol
10. Kerlon
11. Kerlone
12. Oxodal
13. Sl 75212
14. Sl-75212
15. Sl75212
1. 63659-19-8
2. Betaxolol Hcl
3. Betoptic
4. Kerlone
5. Betoptima
6. Lokren
7. Betaxolol (hydrochloride)
8. Alo 1401-02
9. Sl75212
10. Betaxolol Hydrochloride (betoptic)
11. Nsc-760048
12. Alo-1401-02
13. Betoptic S
14. Mls000863279
15. 6x97d2xt0o
16. Dextrobetaxolol (hydrochloride)
17. Kerlon
18. 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydrochloride
19. Alo-140102
20. Smr000058420
21. Sl-7521210
22. Sl 75.212-10
23. Sl-75.212-10
24. 1-(isopropylamino)-3-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)propan-2-ol Hydrochloride
25. Betaxolo Hydrochloride
26. 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanol Hydrochloride
27. 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, Hydrochloride, (+-)-
28. Chebi:643228
29. Chemical Name: 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanol Hydrochloride
30. Betaxolol Hydrochloride [usan]
31. Sr-01000000108
32. Einecs 264-384-3
33. Mfcd00242959
34. Sl-75212-10
35. Unii-6x97d2xt0o
36. Kerlong
37. Sl-75212
38. Levobetaxololhcl
39. Sl 75 212-10
40. Betoptic (tn)
41. Prestwick_779
42. Kerlone (tn)
43. Betaxolol Hydrochloride [usan:usp:jan]
44. Cpd000058420
45. Opera_id_878
46. (+-)-1-(p-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)-2-propanol Hydrochloride
47. 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-isopropylaminopropan-2-ol Hydrochloride
48. Chembl1691
49. Schembl42794
50. Mls000028464
51. Mls000758269
52. Mls001148209
53. Mls001424199
54. Mls002222261
55. Betaxolol Hydrochloride- Bio-x
56. Sl 75212 Hcl
57. Betaxolol For Peak Identification
58. Hy-b0381a
59. Dtxsid30979876
60. Mci-144
61. Hms1569m05
62. Pharmakon1600-01505512
63. (2s)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydrochloride
64. Bcp02967
65. Betaxolol Hydrochloride [mi]
66. Tox21_500193
67. Betaxolol Hydrochloride (jp17/usp)
68. Betaxolol Hydrochloride [jan]
69. Nsc760048
70. Akos015843993
71. Ac-1412
72. Bcp9000394
73. Betaxolol Hydrochloride [mart.]
74. Betaxolol Hydrochloride [vandf]
75. Ccg-101057
76. Ccg-213473
77. Lp00193
78. Nc00307
79. Nsc 760048
80. Betaxolol Hydrochloride [usp-rs]
81. Betaxolol Hydrochloride [who-dd]
82. Betaxolol Hydrochloride, >98% (hplc)
83. Ncgc00093669-01
84. Ncgc00093669-02
85. Ncgc00260878-01
86. As-18082
87. Bb164245
88. Bcp0726000249
89. B4474
90. Betaxolol Hydrochloride [orange Book]
91. Eu-0100193
92. Ft-0645228
93. S1827
94. Sw196917-4
95. Betaxolol Hydrochloride [ep Monograph]
96. B 5683
97. Betaxolol Hydrochloride [usp Monograph]
98. D00598
99. T71164
100. Kerledex Component Betaxolol Hydrochloride
101. 659x198
102. A803574
103. Betaxolol Hydrochloride Component Of Kerledex
104. Q-200714
105. Sr-01000000108-2
106. Sr-01000000108-4
107. Sr-01000000108-9
108. Betoptic Pilo Component Betaxolol Hydrochloride
109. Q27105180
110. Betaxolol Hydrochloride Component Of Betoptic Pilo
111. Betaxolol Hydrochloride, European Pharmacopoeia (ep) Reference Standard
112. Betaxolol Hydrochloride, United States Pharmacopeia (usp) Reference Standard
113. 1-(isopropylamino)-3-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)propan-2-ol Hcl
114. 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydron;chloride
115. 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanolhydrochloride
116. Betaxolol For Peak Identification, European Pharmacopoeia (ep) Reference Standard
117. (+/-)-1-(p-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)-2-propanol Hydrochloride
118. 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)propan-2-ol Hydrochloride;levobetaxolol Hydrochloride
119. 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, Hydrochloride, (+/-)-
120. 72424-72-7
Molecular Weight | 343.9 g/mol |
---|---|
Molecular Formula | C18H30ClNO3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 11 |
Exact Mass | 343.1914215 g/mol |
Monoisotopic Mass | 343.1914215 g/mol |
Topological Polar Surface Area | 50.7 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 286 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Betaxolol hydrochloride |
PubMed Health | Betaxolol (Into the eye) |
Drug Classes | Antiglaucoma |
Drug Label | Betaxolol Ophthalmic Solution USP, contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile isotonic solution. Betaxolol hydrochloride is a white, crystalline powder, soluble in water, with a molecular... |
Active Ingredient | Betaxolol hydrochloride |
Dosage Form | Solution/drops; Tablet |
Route | Ophthalmic; Oral |
Strength | 10mg; eq 0.5% base; 20mg |
Market Status | Prescription |
Company | Wockhardt; Epic Pharma; Kvk Tech; Bausch And Lomb; Akorn |
2 of 6 | |
---|---|
Drug Name | Betoptic |
PubMed Health | Betaxolol (Into the eye) |
Drug Classes | Antiglaucoma |
Drug Label | BETOPTIC Sterile Ophthalmic Solution contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile isotonic solution. Betaxolol hydrochloride is a white, crystalline powder, soluble in water, with a molec... |
Active Ingredient | Betaxolol hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.5% base |
Market Status | Prescription |
Company | Alcon |
3 of 6 | |
---|---|
Drug Name | Betoptic s |
Active Ingredient | Betaxolol hydrochloride |
Dosage Form | Suspension/drops |
Route | Ophthalmic |
Strength | eq 0.25% base |
Market Status | Prescription |
Company | Alcon |
4 of 6 | |
---|---|
Drug Name | Betaxolol hydrochloride |
PubMed Health | Betaxolol (Into the eye) |
Drug Classes | Antiglaucoma |
Drug Label | Betaxolol Ophthalmic Solution USP, contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile isotonic solution. Betaxolol hydrochloride is a white, crystalline powder, soluble in water, with a molecular... |
Active Ingredient | Betaxolol hydrochloride |
Dosage Form | Solution/drops; Tablet |
Route | Ophthalmic; Oral |
Strength | 10mg; eq 0.5% base; 20mg |
Market Status | Prescription |
Company | Wockhardt; Epic Pharma; Kvk Tech; Bausch And Lomb; Akorn |
5 of 6 | |
---|---|
Drug Name | Betoptic |
PubMed Health | Betaxolol (Into the eye) |
Drug Classes | Antiglaucoma |
Drug Label | BETOPTIC Sterile Ophthalmic Solution contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile isotonic solution. Betaxolol hydrochloride is a white, crystalline powder, soluble in water, with a molec... |
Active Ingredient | Betaxolol hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.5% base |
Market Status | Prescription |
Company | Alcon |
6 of 6 | |
---|---|
Drug Name | Betoptic s |
Active Ingredient | Betaxolol hydrochloride |
Dosage Form | Suspension/drops |
Route | Ophthalmic |
Strength | eq 0.25% base |
Market Status | Prescription |
Company | Alcon |
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Adrenergic beta-1 Receptor Antagonists
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Antagonists.)
Sympatholytics
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)
M2i Group, an integrated CDMO, is your French partner for development & manufacturing in fine chemistry.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Certificate Number : R1-CEP 2009-344 - Rev 01
Issue Date : 2016-12-08
Type : Chemical
Substance Number : 1072
Status : Withdrawn by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25301
Submission : 2011-09-22
Status : Active
Type : II
Certificate Number : R1-CEP 2011-031 - Rev 01
Issue Date : 2020-04-07
Type : Chemical
Substance Number : 1072
Status : Valid
Date of Issue : 2019-08-16
Valid Till : 2022-08-15
Written Confirmation Number : WC-0151
Address of the Firm :
NDC Package Code : 14445-002
Start Marketing Date : 2013-12-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10727
Submission : 1994-02-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17235
Submission : 2004-02-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12680
Submission : 1997-10-02
Status : Inactive
Type : II
Registration Number : 218MF10546
Registrant's Address : Strada Rivoltana Km 6/7 20053 Rodano Milano Italy
Initial Date of Registration : 2006-06-02
Latest Date of Registration :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12638
Submission : 1997-08-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8662
Submission : 1990-07-19
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3800
Submission : 1980-05-09
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
33
PharmaCompass offers a list of Betaxolol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Betaxolol manufacturer or Betaxolol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Betaxolol manufacturer or Betaxolol supplier.
PharmaCompass also assists you with knowing the Betaxolol API Price utilized in the formulation of products. Betaxolol API Price is not always fixed or binding as the Betaxolol Price is obtained through a variety of data sources. The Betaxolol Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Betaxolol HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Betaxolol HCl, including repackagers and relabelers. The FDA regulates Betaxolol HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Betaxolol HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Betaxolol HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Betaxolol HCl supplier is an individual or a company that provides Betaxolol HCl active pharmaceutical ingredient (API) or Betaxolol HCl finished formulations upon request. The Betaxolol HCl suppliers may include Betaxolol HCl API manufacturers, exporters, distributors and traders.
click here to find a list of Betaxolol HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Betaxolol HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of Betaxolol HCl active pharmaceutical ingredient (API) in detail. Different forms of Betaxolol HCl DMFs exist exist since differing nations have different regulations, such as Betaxolol HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Betaxolol HCl DMF submitted to regulatory agencies in the US is known as a USDMF. Betaxolol HCl USDMF includes data on Betaxolol HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Betaxolol HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Betaxolol HCl suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Betaxolol HCl Drug Master File in Japan (Betaxolol HCl JDMF) empowers Betaxolol HCl API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Betaxolol HCl JDMF during the approval evaluation for pharmaceutical products. At the time of Betaxolol HCl JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Betaxolol HCl suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Betaxolol HCl Drug Master File in Korea (Betaxolol HCl KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Betaxolol HCl. The MFDS reviews the Betaxolol HCl KDMF as part of the drug registration process and uses the information provided in the Betaxolol HCl KDMF to evaluate the safety and efficacy of the drug.
After submitting a Betaxolol HCl KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Betaxolol HCl API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Betaxolol HCl suppliers with KDMF on PharmaCompass.
A Betaxolol HCl CEP of the European Pharmacopoeia monograph is often referred to as a Betaxolol HCl Certificate of Suitability (COS). The purpose of a Betaxolol HCl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Betaxolol HCl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Betaxolol HCl to their clients by showing that a Betaxolol HCl CEP has been issued for it. The manufacturer submits a Betaxolol HCl CEP (COS) as part of the market authorization procedure, and it takes on the role of a Betaxolol HCl CEP holder for the record. Additionally, the data presented in the Betaxolol HCl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Betaxolol HCl DMF.
A Betaxolol HCl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Betaxolol HCl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Betaxolol HCl suppliers with CEP (COS) on PharmaCompass.
A Betaxolol HCl written confirmation (Betaxolol HCl WC) is an official document issued by a regulatory agency to a Betaxolol HCl manufacturer, verifying that the manufacturing facility of a Betaxolol HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Betaxolol HCl APIs or Betaxolol HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a Betaxolol HCl WC (written confirmation) as part of the regulatory process.
click here to find a list of Betaxolol HCl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Betaxolol HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Betaxolol HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Betaxolol HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Betaxolol HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Betaxolol HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Betaxolol HCl suppliers with NDC on PharmaCompass.
Betaxolol HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Betaxolol HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Betaxolol HCl GMP manufacturer or Betaxolol HCl GMP API supplier for your needs.
A Betaxolol HCl CoA (Certificate of Analysis) is a formal document that attests to Betaxolol HCl's compliance with Betaxolol HCl specifications and serves as a tool for batch-level quality control.
Betaxolol HCl CoA mostly includes findings from lab analyses of a specific batch. For each Betaxolol HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Betaxolol HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Betaxolol HCl EP), Betaxolol HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Betaxolol HCl USP).